Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic lymphocytic leukemia
Jane Houldsworth(Icahn School of Medicine at Mount Sinai), R. S. K. Chaganti(Leukemia and Lymphoma Society), Jennifer R. Brown(Dana-Farber Cancer Institute), Asha Guttapalli(Cancer Genetics (United States)), Sujata Patil, Nicholas Chiorazzi(Feinstein Institute for Medical Research), Geetu Mendiratta(Icahn School of Medicine at Mount Sinai), Tania Zielonka(Hackensack University Medical Center), Wei‐Yi Chen(Cancer Genetics (United States)), Xiao‐Jie Yan, Anthony R. Mato(University of Pennsylvania), Gouri J. Nanjangud(Memorial Sloan Kettering Cancer Center), Venkata J. Thodima(Cancer Genetics (United States))
Cited by 33
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k